Literature DB >> 30393625

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Giulio Metro1, Massimo Di Maio2.   

Abstract

Entities:  

Year:  2018        PMID： 30393625      PMCID： PMC6193898          DOI： 10.21037/tlcr.2018.07.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Authors:  Zhong-Yi Dong; Jia-Tao Zhang; Si-Yang Liu; Jian Su; Chao Zhang; Zhi Xie; Qing Zhou; Hai-Yan Tu; Chong-Rui Xu; Li-Xu Yan; Yu-Fa Li; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Oncoimmunology       Date:  2017-07-26       Impact factor: 8.110

3.  Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Authors:  Scott Gettinger; Leora Horn; David Jackman; David Spigel; Scott Antonia; Matthew Hellmann; John Powderly; Rebecca Heist; Lecia V Sequist; David C Smith; Philip Leming; William J Geese; Dennis Yoon; Ang Li; Julie Brahmer
Journal:  J Clin Oncol       Date:  2018-03-23       Impact factor: 44.544

Review 4.  Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Authors:  Ross A Soo; Sun Min Lim; Nicholas L Syn; Rebecca Teng; Richie Soong; Tony S K Mok; Byoung Chul Cho
Journal:  Lung Cancer       Date:  2017-11-13       Impact factor: 5.705

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Authors:  Nan Chen; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Yanna Tang; Shiyang Kang; Yaxiong Zhang; Xiaobo He; Ting Zhou; Tao Qin; Yan Huang; Xianping Yi; Li Zhang
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Authors:  Benjamin J Solomon; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Yiyun Tang; Keith D Wilner; Fiona Blackhall; Tony S Mok
Journal:  J Clin Oncol       Date:  2018-05-16       Impact factor: 44.544

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Wendy Cooper; Matthew Links; Val Gebski; Roy S Herbst; Richard J Gralla; Tony Mok; James Chih-Hsin Yang
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.